Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Apr:7:506-511.
doi: 10.1200/GO.20.00269.

PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience

Amit Agarwal  1 , Saphalta Baghmar  1 , Chandragouda Dodagoudar  1 , Suhail Qureshi  1 , Aseem Khurana  1 , Vikas Vaibhav  2 , Guresh Kumar  3
Affiliations
Randomized Controlled Trial

PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience

Amit Agarwal et al. JCO Glob Oncol. 2021 Apr.

Abstract

Purpose: Poly (ADP-ribose) polymerase inhibitors (PARPi) have proven efficacy in treatment of BReast CAncer (BRCA) gene mutation-positive platinum-sensitive ovarian cancers. There is paucity of data for their role in platinum-resistant ovarian cancer (PROC). We report here retrospective analysis of outcome of PARPi treatment in a group of patients including those of PROC.

Patients and methods: We analyzed all consecutive patients who received PARPi. The efficacy of PARPi monotherapy was assessed in patients with relapsed high-grade serous ovarian carcinoma with gBRCAm. The drug was procured through compassionate program. Drugs (olaparib and talazoparib) were provided in capsule form.

Results: Between July 1, 2015, and June 30, 2019, 28 patients with ovarian cancer received PARPi. At the time of data censoring (September 30, 2019), four (14.3%) patients are still on treatment. Median age was 54.5 years (range, 39-75 years). Median number of previous lines of chemotherapy received was three (range, 1-6). Eleven platinum-sensitive patients received the drug as maintenance (five in complete response and six in partial response after chemotherapy), whereas 17 (60.7%) had platinum-resistant progressive disease while starting the drug. In PROC, objective response rate (complete response plus partial response) was 47%, median progression-free survival was 8.2 months (5.3-11.3), and overall survival was 14.9 months (11.2-18.5). No new side effects were observed.

Conclusion: This is the first study from India evaluating PARPi in platinum-resistant ovarian cancer. This study suggests that PARPi is a viable treatment option in patients with PROC with gBRCAm. This should be further evaluated in randomized clinical trial.

PubMed Disclaimer

Conflict of interest statement

Amit AggarwalEmployment: LillyStock and Other Ownership Interests: LillyNo other potential conflicts of interest were reported.

Figures

FIG 1
FIG 1
PFS in PSOC and PROC cases. PFS, progression-free survival; PROC, platinum-resistant ovarian cancer; PSOC, platinum-sensitive ovarian cancer.
FIG 2
FIG 2
OS in PSOC and PROC cases. OS, overall survival; PROC, platinum-resistant ovarian cancer; PSOC, platinum-sensitive ovarian cancer.
See this image and copyright information in PMC

References

    1. www.uicc.org/new-global-cancer-data-globocan-2018
    1. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 951320–13292003 - PubMed
    1. Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer J Clin Oncol 183084–30922000 - PubMed
    1. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group Study J Clin Oncol 213194–32002003 - PubMed
    1. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the Gynecologic Cancer Intergroup J Clin Oncol 271419–14252009 - PMC - PubMed

Publication types

Substances